lair1 overexpression cassette (Shanghai Genechem Ltd)
Structured Review

Lair1 Overexpression Cassette, supplied by Shanghai Genechem Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lair1+overexpression+cassette/cassette+lair1+overexpression/pmc13265161-79-24-32
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "Unveiling LAIR1: a prognostic biomarker associated with gastric cancer progression and metastasis"
Article Title: Unveiling LAIR1: a prognostic biomarker associated with gastric cancer progression and metastasis
Journal: Translational Cancer Research
doi: 10.21037/tcr-2026-1-0136
Figure Legend Snippet: Bioinformatic analysis of LAIR1 expression in pan-cancer and its prognostic value in GC. (A) LAIR1 expression across cancers from TIMER2. (B-D) Poor prognosis associated with high LAIR1 expression (probe 208071_s_at) in GC: (B) OS, (C) FPS, (D) PPS. (E-G) Poor prognosis associated with high LAIR1 expression (probe 210644_s_at) in GC: (E) OS, (F) FPS, (G) PPS. *, P<0.05; ***, P<0.001. CI, confidence interval; FPS, first progression survival; GC, gastric cancer; HR, hazard ratio; LAIR1, leukocyte-associated immunoglobulin-like receptor 1; OS, overall survival; PPS, post-progression survival; TPM, transcripts per million.
Techniques Used: Expressing
Figure Legend Snippet: Expression and prognostic analysis of LAIR1 in GC. (A) Representative images showing low LAIR1 expression in normal gastric tissue and high expression in GC tissue. Negative staining (IHC scores 1–2), weak staining (IHC scores 3–4), moderate staining (IHC scores 6–9), and strong staining (IHC scores 12). (B) OS based on LAIR1 expression status. (C) PFS based on LAIR1 expression status. (D) LAIR1 protein expression in 16 paired GC tissues (N: adjacent normal; T: tumor). (E) LAIR1 mRNA levels in the same 16 paired tissues. ****, P<0.0001. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GC, gastric cancer; IHC, immunohistochemistry; LAIR1, leukocyte-associated immunoglobulin-like receptor 1; mRNA, messenger RNA; OS, overall survival; PFS, progression-free survival.
Techniques Used: Expressing, Negative Staining, Staining, Immunohistochemistry
Figure Legend Snippet: LAIR1 expression and its impact on GC cell proliferation. (A) LAIR1 protein levels in various GC cell lines. (B) Statistical analysis of LAIR1 expression across cell lines. (C) Validation of LAIR1 knockdown efficiency via lentivirus in MGC803 cells. (D) Validation of LAIR1 overexpression efficiency in MKN45 cells. (E) Effect of LAIR1 knockdown on cell viability (CCK-8). (F) Effect of LAIR1 overexpression on cell viability (CCK-8). (G) Colony formation after LAIR1 knockdown in MGC803 cells (crystal violet staining). (H) Colony formation after LAIR1 overexpression in MKN45 cells (crystal violet staining). **, P<0.01; ***, P<0.001; ****, P<0.0001; ns, not significant. CCK-8, Cell Counting Kit-8; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GC, gastric cancer; LAIR1, leukocyte-associated immunoglobulin-like receptor 1; NC, negative control; sh-1, shLAIR1-1; sh-2, shLAIR1-2; shLAIR1, short hairpin RNA targeting LAIR1.
Techniques Used: Expressing, Biomarker Discovery, Knockdown, Over Expression, CCK-8 Assay, Staining, Cell Counting, Negative Control, shRNA
Figure Legend Snippet: Effect of LAIR1 on GC cell migration and invasion. (A) Scratch wound assay in LAIR1-knockdown MGC803 cells. (B) Scratch wound assay in LAIR1-overexpressing MKN45 cells. (C) Transwell invasion assay in LAIR1-knockdown MGC803 cells (crystal violet staining). (D) Transwell invasion assay in LAIR1-overexpressing MKN45 cells (crystal violet staining). ***, P<0.001; ****, P<0.0001. GC, gastric cancer; LAIR1, leukocyte-associated immunoglobulin-like receptor 1; NC, negative control; sh-1, shLAIR1-1; sh-2, shLAIR1-2; shLAIR1, short hairpin RNA targeting LAIR1.
Techniques Used: Migration, Scratch Wound Assay Assay, Knockdown, Transwell Invasion Assay, Staining, Negative Control, shRNA
Figure Legend Snippet: Effect of LAIR1 knockdown on subcutaneous tumor growth in nude mice. (A) Tumorigenesis in nude mice following LAIR1 downregulation. (B,C) Tumor progression: significant differences in subcutaneous tumor growth curves (B) and final tumor weights (C). (D) IHC scores for LAIR1 and Ki-67. (E) Representative IHC images for LAIR1. (F) Representative IHC images for Ki-67. **, P<0.01; ****, P<0.0001. IHC, immunohistochemistry; LAIR1, leukocyte-associated immunoglobulin-like receptor 1; NC, negative control; shLAIR1, short hairpin RNA targeting LAIR1.
Techniques Used: Knockdown, Immunohistochemistry, Negative Control, shRNA
Figure Legend Snippet: Effect of LAIR1 knockdown on peritoneal metastasis in nude mice. (A) Representative images of peritoneal metastatic nodules. (B) The number of nodules in the peritoneal metastases of nude mice exhibited significant variations. (C) IHC scores for LAIR1, Snail1, N-cadherin, and E-cadherin. (D-G) Representative IHC images for LAIR1 (D), Snail1 (E), N-cadherin (F), and E-cadherin (G). *, P<0.05; **, P<0.01; ****, P<0.0001. IHC, immunohistochemistry; LAIR1, leukocyte-associated immunoglobulin-like receptor 1; NC, negative control; shLAIR1, short hairpin RNA targeting LAIR1.
Techniques Used: Knockdown, Immunohistochemistry, Negative Control, shRNA
Figure Legend Snippet: Effect of LAIR1 knockdown on lung and lymph node metastasis in nude mice. (A) Gross view of lung metastasis. (B) Lung metastatic nodules visualized by H&E staining. (C) Quantitative analysis of metastatic lung nodules. (D) Gross view of lymph node metastasis. (E) Quantitative analysis of metastatic lymph nodes. **, P<0.01; ****, P<0.0001. H&E, hematoxylin-eosin; LAIR1, leukocyte-associated immunoglobulin-like receptor 1; NC, negative control; shLAIR1, short hairpin RNA targeting LAIR1.
Techniques Used: Knockdown, Staining, Negative Control, shRNA